Cystatin A was chosen for further analysis and experiments since a protein that is upregulated in the vaginal microenvironment is a preferable biomarker, and replicated upregulation indicates that cystatin A detection is indeed observed with an increase of tumor burden as opposed to being a byproduct of the vaginal lavages. The gene discussed is CSTA; the disease is neoplasm.